Newly published treatment algorithm for the pharmacologic treatment of obesity and its complications, from the European Association for the Study of Obesity (EASO) ⚕️ Semaglutide and tirzepatide are recommended as first line to treat obesity AND to treat underlying obesity-related complications. This framework incorporates weight management ⚖️ and complications management into equal goals. Treat the adipose tissue accumulation to prevent organ dysfunction AND reverse organ dysfunction🫀🫁 Recommendations based on their own meta-analysis 📊, both published today 🗓️. EASO Framework: nature.com/articles/s41591-0… Meta-analysis: nature.com/articles/s41591-0…

Skeletal muscle 💪 should be viewed as a vital metabolic organ 🧬. Preserving lean mass during weight loss ⚖️ is essential for physical performance 🏃‍♂️ and long-term metabolic health ❤️‍🩹. The risks of muscle loss, from impaired gly-caemic control 🩸 to loss of independence 🧑‍🦽, must be addressed proactively ⚠️. Muscle loss ❌💪 must not be the cost if adipose tissue loss 🧊➡️🔥 is the goal 🎯 pubmed.ncbi.nlm.nih.gov/4072…

How do we learn? Life—and medicine—is built on automatic moves, as we're usually good at predicting what comes next. But consciousness arises from prediction errors. And only through consciousness can learning happen!

🚨 New in @AGA_CGH 🚨 Waist-to-height ratio (WHtR) >>> BMI/waist in predicting: 🔑 Severe hepatic steatosis (AUROC 0.79) 🔑Advanced fibrosis (AUROC 0.78) 🔑 Especially effective in Hispanics @ebtapper @EndoDialogues @PittIMChiefs @PittGIM @BIDMC_GI cghjournal.org/article/S1542…

Subcutaneous semaglutide demonstrated cardiovascular benefit in T2DM back in 2016 (SUSTAIN-6) with 26% MACE reduction. Oral semaglutide demonstrates cardiovascular risk reduction in T2DM and high CV risk in the newly published SOUL trial with 14% MACE reduction with albeit a low 14mg oral daily dose. nejm.org/doi/full/10.1056/NE…